A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults.
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2007
At a glance
- Drugs Resiquimod (Primary)
- Indications Warts
- Focus Therapeutic Use
- 16 Feb 2007 Companies (Medicis Pharmaceutical Corporation, Graceway Pharmaceuticals) identified as trial sponsor and aditional lead centre reported by ClinicalTrials.gov.
- 18 Nov 2005 New trial record.